We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
+27.37%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$563M
AUM Growth
+$52.1M
Cap. Flow
-$54.1M
Cap. Flow %
-9.6%
Top 10 Hldgs %
49.74%
Holding
65
New
13
Increased
15
Reduced
18
Closed
8

Top Buys

Rank Stock Value
1
NUVA
NuVasive, Inc.
NUVA
+$7.38M
2
ACGN
Aceragen Inc
ACGN
+$6.67M
3
SPNC
Spectranetics Corp
SPNC
+$6.23M
4
TXMD icon
TherapeuticsMD
TXMD
+$5.15M
5
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$4.96M

Top Sells

Rank Stock Value
1
NPSP
NPS PHARMACEUTICALS INC
NPSP
+$28.6M
2
IART icon
Integra LifeSciences
IART
+$11.1M
3
IPXL
Impax Laboratories, Inc.
IPXL
+$9.83M
4
ARTC
ARTHROCARE CORP
ARTC
+$9.17M
5
HITK
HI-TECH PHARMACAL INC
HITK
+$9.07M

Sector Composition

Rank Sector Weight
1 Healthcare 77.84%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SLTM
26
DELISTED
SOLTA MED INC (DE)
SLTM
$6.89M 1.22%
3,328,135
-600,000
-15% -$1.36M
HZNP
27
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$6.3M 1.12%
+1,880,000
New +$4.96M
TXMD icon
28
TherapeuticsMD
TXMD
$23.8M
$6.24M 1.11%
+42,563
New +$5.15M
CRDC
29
DELISTED
CARDICA INC COM NEW (DE)
CRDC
$6.2M 1.1%
477,267
+38,695
+9% +$474K
GWPH
30
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$5.7M 1.01%
332,936
+52,936
+19% +$608K
ASMB icon
31
Assembly Biosciences
ASMB
$506M
$5.35M 0.95%
30,831
– –
INFI
32
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$5.05M 0.9%
290,000
+172,828
+147% +$3.31M
MASI
33
DELISTED
Masimo
MASI
$4.42M 0.78%
165,837
-85,000
-34% -$2.1M
GMED icon
34
Globus Medical
GMED
$10.4B
$4.34M 0.77%
248,767
– –
WINT
35
DELISTED
Windtree Therapeutics Inc
WINT
$4.25M 0.75%
154,714
+35,714
+30% +$866K
ZGNX
36
DELISTED
Zogenix, Inc.
ZGNX
$3.68M 0.65%
248,456
+114,894
+86% +$1.54M
POZN
37
DELISTED
POZEN INC
POZN
$3.67M 0.65%
641,000
– –
QLTI
38
DELISTED
QLT Inc
QLTI
$3.63M 0.65%
784,893
– –
DRTX
39
DELISTED
DURATA THERAPEUTICS INC COM STK (DE)
DRTX
$3.46M 0.61%
383,227
– –
IPCI
40
DELISTED
Intellipharmaceuticals International Inc.
IPCI
$3.44M 0.61%
175,626
-20,452
-10% -$402K
ALBO
41
DELISTED
Albireo Pharma Inc
ALBO
$3.15M 0.56%
33,333
+18,007
+117% +$2.34M
OFIX icon
42
Orthofix Medical
OFIX
$455M
$3.15M 0.56%
151,523
-98,477
-39% -$2.39M
ANTH
43
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$2.86M 0.51%
89,062
+23,437
+36% +$727K
FLNA
44
Filana Therapeutics
FLNA
$43M
$2.72M 0.48%
142,857
– –
INSM icon
45
Insmed
INSM
$23.2B
$2.58M 0.46%
165,145
-126,595
-43% -$1.61M
NVAX icon
46
Novavax
NVAX
$1.23B
$2.52M 0.45%
+40,000
New +$2.25M
FRX
47
DELISTED
FOREST LABORATORIES INC
FRX
$2.14M 0.38%
+50,000
New +$2.17M
CUTR
48
DELISTED
Cutera, Inc.
CUTR
$1.92M 0.34%
215,962
– –
HTWR
49
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
$1.83M 0.32%
+25,000
New +$2.13M
TNXP icon
50
Tonix Pharmaceuticals
TNXP
$157M
– –
0
– –
1
2
3

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q3 2013 Portfolio in Review

As of Q3 2013, Broadfin Capital held 65 positions worth $563M, up 10% from $511M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Broadfin Capital withdrew a net $54.1M in Q3 2013, closing 8 positions and reducing 18 holdings. Its most notable exit was ARTHROCARE CORP, an estimated $9.17M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 73% a quarter earlier.

Against the trend, Broadfin Capital opened a new position in NuVasive, Inc. worth $7.35M.

  • Broadfin Capital's largest Q3 2013 buy was NuVasive, Inc.: 300,000 shares worth $7.35M.
  • Broadfin Capital added most to Spectranetics Corp in Q3 2013, an estimated $6.23M increase.
  • Broadfin Capital's biggest Q3 2013 reduction was NPS PHARMACEUTICALS INC, cutting an estimated $28.6M.
  • Broadfin Capital fully exited ARTHROCARE CORP in Q3 2013, selling an estimated $9.17M.
  • Broadfin Capital's ten largest holdings make up 50% of its $563M portfolio in Q3 2013.
  • Broadfin Capital opened 13 new positions and closed 8 in Q3 2013.
  • Broadfin Capital's portfolio value rose 10% quarter-over-quarter to $563M.

Based on Broadfin Capital's 13F filing for Q3 2013, filed 14 Nov 2013.